Evidence map›Paper›PMID 42346208›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada.

Alexis T Mickle, Frances Simbulan, Bianca Li, Kristoph Klein-Panneton, Conor L Morrison, Sarah Walker, Karissa M Johnston, Stephanie Snow

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alexis T MickleBroadstreet HEOR, 177 W 7th Ave, Vancouver, BC V5Y 1L8, Canada.ORCID 0009-0004-2884-1167
Frances SimbulanAstraZeneca Canada Inc., 1004 Middlegate Rd, Mississauga, ON L4Y 1M4, Canada.
Bianca LiAstraZeneca Canada Inc., 1004 Middlegate Rd, Mississauga, ON L4Y 1M4, Canada.
Kristoph Klein-PannetonAstraZeneca Canada Inc., 1004 Middlegate Rd, Mississauga, ON L4Y 1M4, Canada.ORCID 0009-0002-0683-8771
Conor L MorrisonBroadstreet HEOR, 177 W 7th Ave, Vancouver, BC V5Y 1L8, Canada.ORCID 0009-0000-4712-1828
Sarah WalkerBroadstreet HEOR, 177 W 7th Ave, Vancouver, BC V5Y 1L8, Canada.ORCID 0009-0009-0807-8543
Karissa M JohnstonBroadstreet HEOR, 177 W 7th Ave, Vancouver, BC V5Y 1L8, Canada.
Stephanie SnowQEII Health Sciences Centre, Dalhousie University, 1796 Summer St, Halifax, NS B3H 3A7, Canada.ORCID 0000-0003-3847-0289

Funding

AstraZeneca (Canada) n/a
6 · The paper itself

Abstract

To quantify preferences and trade-offs for non-overall survival (OS) endpoints among Canadian adults treated for early-stage cancers, participants completed ten choice sets in a discrete choice experiment. Standard-of-care (SoC) was compared to new treatment profiles defined by five attributes: five-year OS, two-year disease advancement, pathological complete response (pCR), and short- and long-term side effects. SoC attribute levels remained constant across respondents, except OS, which varied. For the new treatment, all attributes except OS (fixed as unknown) varied. Data were analyzed using logistic regression and presented as odds ratios (ORs) with 95% confidence intervals (CIs). Among 103 adults treated for early-stage gastrointestinal (

Indexed as

NeoplasmsPatient PreferenceAdultAgedCanadaChoice BehaviorClinical Trials as TopicFemaleHumansMaleMiddle AgedNeoplasm Stagingclinical trial endpointsdiscrete choice experimentdisease-free survivalearly-stage cancerhealth care surveysoverall survivalpatient preferenceprogression-free survivalsurrogate endpoint

Identifiers

PMID42346208
PMCPMC13297726

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.